Search results for "From ACP Journal Club"
In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality
The results of the meta-analysis support recommendations to use sodium-glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes patients who have or are at high risk for cardiovascular (CV) disease, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/03/11/8.htm
11 Mar 2022
In obesity with T2DM, biliopancreatic diversion increased T2DM remission vs. medical and lifestyle therapy at 10 y
Previous research has shown short-term remission of type 2 diabetes after bariatric surgery, but a decade of data from this randomized trial should reassure patients of the favorable long-term benefits and safety of this intervention, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/06/11/9.htm
11 Jun 2021
In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs
A meta-analysis identified relative benefits of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) based on individual cardiovascular and renal risks.
https://diabetes.acponline.org/archives/2021/06/11/8.htm
11 Jun 2021
Intensive weight management in primary care improved weight loss and remission of type 2 diabetes
The author of an ACP Journal Club commentary said that the intervention effect was strong enough to prompt a reconsideration of primary care management of obesity and that the results of the trial may motivate patients to lose enough weight to reverse diabetes.
https://diabetes.acponline.org/archives/2018/04/13/8.htm
13 Apr 2018
SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes
Diabetic ketoacidosis (DKA) is rare with sodium-glucose co-transporter-2 (SGLT2) inhibitors but more common than with control medications, and clinicians should be vigilant in identifying euglycemic DKA in patients on these drugs, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/11/13/6.htm
13 Nov 2020
Review compares effectiveness, cost, and safety of second-line drugs for diabetes
The review found that sulfonylureas were more cost-effective than newer agents, but an ACP Journal Club commentary stressed the importance of shared decision making in the choice of a second agent.
https://diabetes.acponline.org/archives/2018/02/09/6.htm
9 Feb 2018
In type 2 diabetes, the BT-001 smartphone app reduced HbA1c more than a control app at 90 d
The availability of an app that delivers cognitive behavioral therapy to patients with diabetes could have meaningful clinical effects, but it remains to be seen whether behavior changes are sustained long-term, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/01/13/10.htm
13 Jan 2023
In men who are overweight or obese, adding testosterone therapy reduced glucose intolerance/T2DM
A industry-funded trial found improved glucose control in men randomized to testosterone injections, but some of its claims were exaggerated, and routine use of testosterone therapy to prevent or reverse type 2 diabetes is not recommended, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/05/14/7.htm
14 May 2021
Review: Rapid-acting analogues do not differ from regular human insulin for mortality or HbA1c in type 2 diabetes
The review shows that, contrary to specialty recommendations, there is no reason not to use regular human insulins, which are less costly than analogue insulins, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/05/10/7.htm
10 May 2019
Review: Evidence is inconclusive on metabolic surgery vs. medical treatment for microvascular complications in T2DM
A meta-analysis from earlier this year that compared the effects of metabolic surgery and medical treatment found 10 studies to include, only three of them randomized controlled trials.
https://diabetes.acponline.org/archives/2018/08/10/7.htm
10 Aug 2018